New directions in hepatitis B therapy research

Marta Lewandowska; Anna Piekarska

doi:10.5114/ceh.2017.68831

eISSN: 2449-8238
ISSN: 2392-1099

Clinical and Experimental Hepatology

Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2017
vol. 3

Send email

Copy url:

abstract:

Review paper

New directions in hepatitis B therapy research

Marta Lewandowska

,

Anna Piekarska

Clin Exp HEPATOL 2017; 3, 3: 119–126

DOI: https://doi.org/10.5114/ceh.2017.68831

Online publish date: 2017/07/05

View full text Get citation

PlumX metrics:

Chronic hepatitis B treatment is available for a long period, allowing disease control and infection suppression, but it is rarely responsible for HBsAg clearance. None of the drugs available aim at cccDNA, the obstacle in HBV infection eradication. Complications related to CHB, such as liver insufficiency, cirrhosis, and hepatocellular carcinoma are reduced in conditions of good viremia suppression, but still exist even after HBsAg seroclearance, what makes a need for urgent forthcoming of new therapeutics. Recent years brought promising and interesting results of experimental approaches, which are directed against different phases of HBV life cycle, target ccc DNA, or boost, and restore host immune response. Unfortunately, encouraging results in vitro and on animal models are not always reflected in human. Nevertheless, the multiplicity of novel antivirals allows to expect that at least some of them will enter clinical practice and relieve patients from chronic hepatitis B, fatal and devastating disease.

keywords:

New directions in hepatitis B therapy research

Marta Lewandowska , Anna Piekarska

HBV life cycle, cccDNA silencing, novel HBV antivirals, immunotherapeutics

Marta Lewandowska

,

Anna Piekarska